Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Decrease in Short Interest

Entera Bio Ltd. (NASDAQ:ENTX) saw a large decrease in short interest during the month of December. As of December 31st, there was short interest totalling 47,300 shares, a decrease of 23.1% from the December 15th total of 61,500 shares. Based on an average trading volume of 122,300 shares, the days-to-cover ratio is presently 0.4 days.

Entera Bio Stock Up 4.9 %

Shares of NASDAQ ENTX opened at $2.34 on Friday. The stock has a market capitalization of $83.73 million, a PE ratio of -9.00 and a beta of 1.49. The firm has a fifty day moving average of $2.04 and a 200-day moving average of $1.87. Entera Bio has a 52-week low of $0.68 and a 52-week high of $3.35.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Entera Bio in a research report on Monday, November 11th.

Institutional Investors Weigh In On Entera Bio

A hedge fund recently bought a new stake in Entera Bio stock. Signature Estate & Investment Advisors LLC acquired a new stake in Entera Bio Ltd. (NASDAQ:ENTX) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 47,328 shares of the company’s stock, valued at approximately $90,000. Signature Estate & Investment Advisors LLC owned approximately 0.13% of Entera Bio at the end of the most recent reporting period. 14.11% of the stock is owned by hedge funds and other institutional investors.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.